Abstract
Platform and basket trial have the potential to alter the landscape of drug development in many disease areas. Although these trials create many efficiencies compared with simple trials, they also create new statistical challenges for regulators. I highlight some of these new issues and discuss the regulatory challenges emerging from these trials. I highlight some critical points made by Collignon et al.,1 while providing some conflicting views on these statistical challenges.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
